HomeCompareMYOV vs ORCC

MYOV vs ORCC: Dividend Comparison 2026

MYOV yields 7.41% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MYOV wins by $11.3K in total portfolio value
10 years
MYOV
MYOV
● Live price
7.41%
Share price
$26.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.7K
Annual income
$1,186.18
Full MYOV calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — MYOV vs ORCC

📍 MYOV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMYOVORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MYOV + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MYOV pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MYOV
Annual income on $10K today (after 15% tax)
$630.10/yr
After 10yr DRIP, annual income (after tax)
$1,008.25/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, MYOV beats the other by $1,007.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MYOV + ORCC for your $10,000?

MYOV: 50%ORCC: 50%
100% ORCC50/50100% MYOV
Portfolio after 10yr
$27.0K
Annual income
$593.61/yr
Blended yield
2.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

MYOV
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.0
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MYOV buys
0
ORCC buys
18
PoliticianChamberTickerTypeAmountDate
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-23
Trey Hollingsworth🏢 House$ORCC▲ Buy$250,001 - $500,0002022-06-16
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-14
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-13
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-10
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-09
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-08
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-03
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-05-24
Trey Hollingsworth🏢 House$ORCC▲ Buy$100,001 - $250,0002022-05-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMYOVORCC
Forward yield7.41%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$32.7K$21.4K
Annual income after 10y$1,186.18$1.04
Total dividends collected$9.7K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: MYOV vs ORCC ($10,000, DRIP)

YearMYOV PortfolioMYOV Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$11,441$741.29$11,190$489.61+$251.00MYOV
2$13,035$792.65$12,229$256.01+$806.00MYOV
3$14,791$843.97$13,216$130.74+$1.6KMYOV
4$16,722$895.04$14,207$66.02+$2.5KMYOV
5$18,838$945.65$15,234$33.17+$3.6KMYOV
6$21,152$995.63$16,317$16.62+$4.8KMYOV
7$23,678$1,044.81$17,468$8.32+$6.2KMYOV
8$26,428$1,093.05$18,695$4.16+$7.7KMYOV
9$29,418$1,140.20$20,006$2.08+$9.4KMYOV
10$32,664$1,186.18$21,407$1.04+$11.3KMYOV

MYOV vs ORCC: Complete Analysis 2026

MYOVStock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Full MYOV Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this MYOV vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MYOV vs SCHDMYOV vs JEPIMYOV vs OMYOV vs KOMYOV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.